

WEIGHT MANAGEMENT & OBESITY

Prepared by:

CPL Business Consultants
The Manor House, Howbery Park, Wallingford, Oxfordshire,
OX10 8BA
Tel: +44 1491 822 844, info@cplconsult.com,
www.cplconsult.com

Dr Esther Hunter
Mr Mattias Bergstrom
Dr Robert Harwood
Dr Steve Lisansky

June 2008

STRATEGIES TO GROW YOUR BUSINESS

TABLE OF CONTENTS

OBJECTIVE 4

BACKGROUND 4

PRINCIPAL FINDINGS..... 5

 OBESITY..... 5

 PHARMACEUTICAL AND OTC 5

 DIETARY SUPPLEMENTS..... 10

CONCLUSIONS 12

 PHARMACEUTICAL & OTC 12

General Plus Points about Pharmaceuticals & OTC..... 13

General Minus Points about Pharmaceutical & OTC..... 13

Plus points for Client about Pharmaceuticals & OTC..... 14

Minus Points for Client about Pharmaceuticals & OTC..... 14

Barriers to Entry in Pharmaceuticals and OTC..... 14

Key Success Factors in Pharmaceuticals and OTC 15

 DIETARY SUPPLEMENTS..... 15

General Plus Points about Dietary Supplements 15

General Minus Points about Dietary Supplements..... 16

Plus points for Client about Dietary Supplements..... 16

Minus Points for Client about Dietary Supplements 17

Barriers to Entry in Supplements 17

Key Success Factors in Supplements..... 17

RECOMMENDATIONS..... 18

PHARMACEUTICAL & OTC MARKET FOR WEIGHT CONTROL 19

 MARKET..... 19

 PRODUCTS & PLAYERS 20

Types of Drugs Currently Used for Treating Obesity..... 20

 DRUGS IN THE PIPELINE 20

Agents in Phase 2 of Clinical Development for Obesity..... 20

Agents in Phase 3 of Clinical Development for Obesity..... 21

 UK..... 21

5 items

 US..... 45

1 item

 NEWS 49

8 items

GENERAL OVERVIEW OF THE GLOBAL PHARMACEUTICAL INDUSTRY 64

 MARKET..... 64

 MARKET FOR ACTIVE PHARMACEUTICAL INGREDIENTS (APIs) 67

 MARKET TRENDS 69

 THE DRUG DEVELOPMENT PROCESS..... 71

Cost of developing a new medicine 71

Drug development and the conduct of medical research..... 72

Clinical trials..... 74

Success rates in Drug Development 77

The promotion of drugs 77

Market Penetration for New Drugs 78

Historical Data..... 79

 INTELLECTUAL PROPERTY PROTECTION 80

Procedures for Drug Approval..... 80

 PLAYERS 81

5 companies

 THE PHARMACEUTICAL INDUSTRY BY REGION..... 97

<i>The US Pharmaceutical Industry</i>	97
<i>The European Pharmaceutical Industry</i>	98
<i>US vs. Europe - Competitive Comparison</i>	118
<i>The Pharmaceutical Industry in the ROW</i>	120
DIETARY SUPPLEMENT MARKET FOR WEIGHT CONTROL	129
INTRODUCTION	129
THE MARKET	130
<i>Trends</i>	132
<i>The market for appetite suppressants</i>	133
PRODUCTS, PLAYERS AND PRICES	133
<i>3 companies</i>	
NEWS	145
<i>9 items</i>	
GENERAL OVERVIEW OF THE GLOBAL DIETARY SUPPLEMENTS INDUSTRY	157
MARKETS.....	157
<i>Value</i>	157
<i>Market Drivers</i>	158
<i>Market Structure</i>	159
<i>Distribution Channels</i>	160
<i>Product and Brand Differentiation</i>	162
<i>Success Factors</i>	162
<i>Barriers to Entry</i>	163
PRODUCTS.....	165
<i>Definitions</i>	165
<i>Product Categories</i>	165
<i>Common dietary supplements and their benefits</i>	167
MAIN PLAYERS	170
<i>US</i>	170
<i>EU</i>	172
REGULATORY.....	174
<i>US</i>	174
<i>EU</i>	178
IP FOR THE USE OF HPMC IN LOWERING CHOLESTEROL	180
<i>Lowering blood cholesterol levels using cellulose ethers</i>	180
<i>Compositions Containing Low Viscosity Hydroxypropyl Methyl Cellulose for Lowering Blood Cholesterol Levels</i>	182
<i>Oral Depressant against Cholesterol</i>	182
<i>Palatable Hydroxypropyl Methylcellulose Ether Powder with Specified Particle Size</i>	183
OBESITY STATISTICS	184

TABLES

TABLE 1	GLOBAL PHARMACEUTICAL MARKET, \$B (2000-2010)	65
TABLE 2	SIZE OF THE PHARMACEUTICAL MARKET, 1985-1999, \$B	79
TABLE 3	LARGEST PHARMACEUTICAL MARKETS (1989-1999), \$M	79
TABLE 4	MARKET CONSOLIDATION IN THE GLOBAL PHARMACEUTICAL INDUSTRY	81
TABLE 5	THE EU PHARMACEUTICAL INDUSTRY IN FIGURES (2004).....	98
TABLE 6	RESEARCH AND DEVELOPMENT IN THE EU PHARMACEUTICAL INDUSTRY (2004).....	99
TABLE 7	THE PHARMACEUTICAL MARKET IN EUROPE, €B (2003)	99
TABLE 8	MARKET SIZE FOR THE CHILEAN PHARMACEUTICAL INDUSTRY, \$M (2003-2005).....	125
TABLE 9	SLIMMING PRODUCT MARKET BY COUNTRY (\$B) 2005	130
TABLE 10	GLOBAL TOTAL WEIGHT MANAGEMENT MARKET BY REGION (\$B), 2001-2009	131
TABLE 11	COMMON SUPPLEMENTS FOR WEIGHT LOSS	134

TABLE 12	AN OVERVIEW OF SUPPLEMENT INGREDIENTS FOR WEIGHT MANAGEMENT	137
TABLE 13	MARKET CONCENTRATION IN THE DIETARY SUPPLEMENT INDUSTRY IN THE US	159
TABLE 14	US DIETARY SUPPLEMENT MARKET BY MANUFACTURER / MARKETER	160
TABLE 15	LIST OF DIETARY SUPPLEMENT PRODUCT CATEGORIES	165
TABLE 16	THE MOST COMMON DIETARY SUPPLEMENTS AND THEIR BENEFITS	167
TABLE 17	MEAN BODY MASS INDEX BY SEX, ADULTS AGED 15 AND OVER, 2002 AND PROJECTIONS FOR 2005 AND 2010, EUROPE.....	184
TABLE 18	PREVALENCE ESTIMATES OF OVERWEIGHT AND OBESITY FOR 2002, AND PROJECTIONS FOR 2005 AND 2010, BY SEX, ADULTS AGED 15 AND OVER, THE WORLD	186

FIGURES

FIGURE 1	COST OF DEVELOPING A NEW MEDICINE (1979 - 2003).....	72
FIGURE 2	DEVELOPMENT OF A DRUG FROM TARGET IDENTIFICATION TO POST-LAUNCH PRODUCT REVIEW	75
FIGURE 3	NEW MOLECULAR ENTITIES APPROVED IN THE US, 1996–2003	75
FIGURE 4	SUCCESS RATES IN DRUG DEVELOPMENT.....	77
FIGURE 5	PERCENTAGE MARKET SHARE FOR PRODUCTS LAUNCHED IN THE LAST FIVE YEARS (2003)	79
FIGURE 6	PHARMACEUTICAL INDUSTRY EXPENDITURE IN R&D IN EUROPE (2002)	99
FIGURE 7	SPLIT OF EUROPEAN PHARMACEUTICAL MARKET (2004)	100
FIGURE 8	FUNDING OF HEALTH-RELATED R&D IN THE UK.....	106
FIGURE 9	COMPARISON OF SHARE OF GLOBAL PHARMACEUTICAL R&D INVESTMENT	107
FIGURE 10	OBESITY AS % OF TOTAL POPULATION IN THE US 1980-2006	129
FIGURE 11	US WEIGHT MANAGEMENT MARKET BY CATEGORY 2005.....	132
FIGURE 12	US DIETARY SUPPLEMENT MARKET BY CATEGORY	157
FIGURE 13	US DIETARY SUPPLEMENT SALES BY MARKET CHANNEL	161